abstract |
The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with antibody drug conjugates (ADCs). In particular, the present disclosure relates to a novel dosage regime for administration of ADCs that bind to CD25 (CD25-ADC). |